证券代码：832471 证券简称：美邦科技 公告编号：2025-045 河北美邦工程科技股份有限公司 2024 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 说明会类型 河北美邦工程科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 在北京证券交易所官方信息披露平台（www.bse.cn）发布了《2024 年年度报告》 （公告编号：2025-019），为方便广大投资者更深入了解公司 2024 年年度经营 业绩的具体情况，加强与投资者的互动交流，公司拟召开 2024 年年度报告业 绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 19 日（星期一）15:00-17:00。 （二）会议召开地点 本次年度报告业绩说明会将采用网络方式召开，投资者可登录全景网"投 资者关系互动平台"（https://ir.p5w.net）参与本次年度报告业绩说明会。 三、 参加人员 公司董事长、总经理：高文杲先生 公司董事、副总经理：张利 ...

证券代码：832471 证券简称：美邦科技 公告编号：2025-044 河北美邦工程科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 □现场参观 □分析师会议 □路演活动 √其他 （网络会议） 二、 投资者关系活动情况 活动时间：2025 年 5 月 9 日至 2025 年 5 月 12 日 活动地点：网络会议 参会单位及人员：开源证券、工银瑞信、东北证券、一创证券、山西证券、 中泰证券、兴业证券、中金公司、长承汇美、中德高路、明德天盛投资管理中心、 广东正圆私募、东吴证券、海南恒立私募、中泰自营、中信建投基金、国寿养老、 长江证券自营、开源证券、南方基金、西南证券、国泰海通、上海天猊投资、长 江证券 上市公司接待人员：公司董事、副总经理、董事会秘书：王晓丽女士；公司 证券事务代表：高子豪先生 三、 投资者关系活动主要内容 本次活动，公司就投资者关心和关注的问题进行了回复，主要问题及回复 情况如下： ...

Group 1: Investor Relations Activities - The investor relations activities included a network meeting held from May 9 to May 12, 2025 [3] - Participating institutions included various securities firms and investment management centers [3] - Company representatives included the board secretary and securities affairs representative [3] Group 2: Financial Performance - The company reported a net profit loss for 2024, primarily due to the shutdown of a production line and asset impairment of CNY 28.292 million [4] - The company's operating revenue for 2024 was CNY 53.959 million, reflecting a year-on-year growth of 12.89% [5] Group 3: Production and Investment Projects - The subsidiary's production line for tetrahydrofuran has entered trial production, with stable operations expected to enhance profitability and market competitiveness [6] - Future optimization of the tetrahydrofuran production line is anticipated to positively impact the company's operational performance [6]

Group 1 - The core viewpoint of the article highlights the financial performance and growth prospects of Meibang Technology, showcasing a revenue increase and strategic advancements in production capacity [1][2] - In 2024, Meibang Technology achieved a revenue of 540 million yuan, representing a year-on-year growth of 12.89%, with the fine chemical products segment contributing 501 million yuan, up 14.55% [1] - The company’s subsidiary, Meibang Zhongke, has initiated trial production of a new 30,000 tons/year tetrahydrofuran production line, which is expected to significantly enhance the supply capacity of core products and expand market share [1] Group 2 - Meibang Technology received multiple authoritative certifications in 2024, including recognition as a "Specialized and Innovative Small and Medium-sized Enterprise" and "High-tech Enterprise," reflecting its strong capabilities in green technology industrialization [2] - The company increased its R&D investment to 24.56 million yuan, a 12.21% increase year-on-year, and secured 16 national patents during the reporting period, enhancing its technological reserves [2] - Looking ahead, Meibang Technology aims to leverage its existing resources to further develop its fine chemicals and solutions business, particularly focusing on synthetic biology to drive sustainable long-term growth [2]

证券代码：832471 证券简称：美邦科技 公告编号：2025-017 河北美邦工程科技股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 29 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2025 年 4 月 18 日以邮件方式发出 5.会议主持人：监事会主席马记 6.召开情况合法、合规、合章程性说明： 本议案尚需提交股东会审议。 本次会议的召开、召集和表决程序符合《公司法》和《公司章程》有关法 律法规以及公司内部治理规则的规定，所作决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于 2024 年度监事会工作报告的议案》 1.议案内容： 根据《公司法》和《公司章程》的规定，由公司监事会主席代表监事会汇 报 2024 年度监事会工作情况。 2.议案表决结 ...

证券代码：832471 证券简称：美邦科技 公告编号：2025-016 河北美邦工程科技股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 29 日 2.会议召开地点：公司会议室 3.会议召开方式：现场及通讯 4.发出董事会会议通知的时间和方式：2025 年 4 月 18 日以邮件方式发出 5.会议主持人：董事长高文杲 6.会议列席人员：监事会成员、董事会秘书及公司高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召开、召集和表决程序符合《公司法》和《公司章程》有关法 律法规以及公司内部治理规则的规定，所作决议合法有效。 本议案无需回避表决。 4.提交股东会表决情况： 本议案无需提交股东会审议。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 二、议案审议情况 （一）审议通过《关于 2024 年度总经理工作报告的议案》 1.议案内容： 根据 ...

2024 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 证券代码：832471 证券简称：美邦科技 公告编号：2025-021 河北美邦工程科技股份有限公司 一、权益分派预案情况 根据公司 2025 年 4 月 29 日披露的 2024 年年度报告（财务报告已经审计）， 截至 2024 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 197,613,481.48 元，母公司未分配利润为 175,599,059.01 元。 公司本次权益分派预案如下：公司目前总股本为 83,200,000 股，根据扣除回 购专户 1,280,000 股后的 81,920,000 股为基数，以未分配利润向全体股东每 10 股 派发现金红利 1.00 元（含税）。本次权益分派共预计派发现金红利 8,192,000 元。 公司将以权益分派实施时股权登记日应分配股数为基数，如股权登记日应分 配股数与目前预计不一致的，公司将维持分派比例不变，并相应调整分派总额。 实际分派结果以中国证券登 ...

Regulatory and Industry Standards - The company participated in the formulation of the national mandatory standard for energy consumption limits in the refining industry, effective from May 1, 2025[4]. - The chemical industry is undergoing a transformation towards high-end, green, and digital development, driven by dual carbon goals and sustainable growth policies[49]. - Recent regulations emphasize the importance of green materials and sustainable practices in the chemical industry, with specific targets set for carbon neutrality and energy efficiency[181]. - The government is promoting the green transformation of traditional manufacturing sectors, including chemicals, to enhance sustainability[184]. Innovation and Research & Development - The company applied for 22 national patents during the reporting period, including 6 invention patents and 16 utility model patents, with 16 patents granted[12]. - The company is actively enhancing its R&D capabilities by attracting high-end scientific personnel to support long-term growth[48]. - The company achieved a research and development expenditure of ¥24,563,871.72, representing 4.55% of operating revenue, compared to ¥21,890,948.27 and 4.58% in the previous period[95]. - The total number of R&D personnel increased from 60 to 67, with the proportion of R&D staff to total employees rising from 17.44% to 18.26%[96]. - The company holds a total of 172 patents, up from 160 in the previous period, including 73 invention patents[97]. Financial Performance - The company’s operating revenue for 2024 was CNY 539,592,663.64, representing a 12.89% increase compared to CNY 477,980,447.37 in 2023[31]. - The net profit attributable to shareholders of the listed company was a loss of CNY 3,452,716.65, a decrease of 115.30% from a profit of CNY 22,569,060.74 in 2023[31]. - The total assets increased by 4.07% to CNY 992,769,159.24 at the end of 2024, compared to CNY 953,964,753.93 at the end of 2023[32]. - The total liabilities rose by 22.59% to CNY 348,225,654.41, up from CNY 284,055,763.20 in 2023[32]. - The gross profit margin for 2024 was 17.53%, slightly up from 17.05% in 2023[31]. Market Position and Strategy - The company is engaged in the research, production, and sales of green technology industrialized products, including tetrahydrofuran and toluene oxidation series products[25]. - The company’s annual production capacity for tetrahydrofuran is projected to reach 30,000 tons, which will increase its market share and position as the largest domestic producer using the LBDO purification method[50]. - The company is positioned within a tight industrial chain cluster, enhancing its competitive edge in the BDO industry[108]. - The company aims to deepen its main business in toluene oxidation series products and tetrahydrofuran, focusing on energy-saving expansion and cost reduction projects to enhance production capacity and economic efficiency[113]. Environmental and Compliance Efforts - The company is committed to sustainable development through the application of synthetic biology and green chemistry principles[111]. - The company maintains a strong focus on environmental protection and compliance with relevant laws and regulations[104]. - The company has implemented measures to address environmental protection risks associated with its production processes, ensuring compliance with pollution control standards[118]. Shareholder and Corporate Governance - The company has initiated a share repurchase plan with a total budget of 10,000,000 to 20,000,000 CNY, aiming to buy back between 781,250 and 1,562,500 shares, which is 0.94% to 1.88% of its total share capital[131]. - The company has successfully completed its share repurchase plan, acquiring 1,280,000 shares at an average price of 12.28 CNY per share, totaling 11,779,583.28 CNY[132]. - The company has established a comprehensive internal control system to enhance risk prevention capabilities and ensure compliance with relevant laws and regulations[115]. - The company has a total of 127,877,500.00 CNY in external guarantees, which accounts for a significant portion of its financial commitments[129]. Human Resources and Employee Development - The total number of employees increased from 344 to 367, with a net addition of 23 employees during the reporting period[171]. - A comprehensive training program has been implemented to improve employee skills and capabilities, including leadership training for mid-level managers and technical training for R&D personnel[174]. - The company has established a human resource planning system aligned with its strategic goals, focusing on competitive compensation and performance incentives to enhance employee motivation[173]. Legal and Risk Management - The company is currently involved in a lawsuit as a defendant, with a cumulative amount of 32,000,000 CNY, representing 4.96% of its net assets[124]. - The company has frozen bank account funds amounting to 32 million yuan due to legal disputes, but other funds in the account remain available for normal operations[137]. - The company has not identified any new major risk factors during the reporting period[120]. - The company has not experienced any significant changes in major risk factors during the reporting period[1].

Financial Performance - Operating revenue for the first quarter of 2025 was CNY 115,716,247.40, down 4.09% year-on-year[8] - Net profit attributable to shareholders for the first quarter of 2025 was a loss of CNY 746,900.07, representing a decline of 130.31% compared to the same period last year[8] - The weighted average return on equity based on net profit attributable to shareholders was -0.14% for the first quarter of 2025, down from 0.44% in the previous year[8] - Net profit for Q1 2025 was a loss of CNY 1,254,527.11, compared to a net profit of CNY 6,227,468.62 in Q1 2024, indicating a significant decline[35] - The total comprehensive income attributable to the parent company was -751,577.04 yuan, compared to 2,464,822.50 yuan in the previous year[36] - Basic and diluted earnings per share were both -0.01 yuan, down from 0.0296 yuan in the same period last year[36] Cash Flow - The net cash flow from operating activities decreased by 69.37% to CNY 3,921,241.83 compared to the previous year[8] - Net cash flow from operating activities amounted to $21,554,054.56, an increase from $16,301,051.07 in the previous period, representing a growth of approximately 32.8%[41] - Cash flow from financing activities generated a net inflow of 19,639,164.86 yuan, compared to a net outflow of -872,597.52 yuan in the previous year[39] - Cash inflow from investment activities was 145,335,639.40 yuan, compared to 10,178,018.58 yuan in the same period last year[39] - The ending balance of cash and cash equivalents was 89,970,075.71 yuan, up from 74,483,947.96 yuan in Q1 2024[39] - The net increase in cash and cash equivalents was -$1,169,509.08, compared to -$7,948,532.21 in the previous period, showing an improvement in cash management[41] Assets and Liabilities - Total assets as of March 31, 2025, were CNY 981,346,351.43, a decrease of 1.15% compared to the end of the previous year[8] - The company's asset-liability ratio (consolidated) was 34.33%, a slight decrease from 35.08% at the end of the previous year[8] - Total liabilities decreased from CNY 348,225,654.41 to CNY 336,871,696.19, a reduction of approximately 3.9%[30] - Total current assets decreased from CNY 436,712,056.22 on December 31, 2024, to CNY 419,696,735.71 on March 31, 2025, a decline of approximately 3.7%[28] - Total non-current assets increased from CNY 556,057,103.02 to CNY 561,649,615.72, a growth of about 1.7%[29] Shareholder Information - The company has a total of 55,243,857 shares held by the top ten shareholders, representing 66.39% of the total shares[17] - The largest shareholder, Gao Wengao, holds 27.67% of the shares, with a total of 23,022,000 shares[16] Research and Development - Research and development expenses increased by 66.65% to CNY 7,696,788.65 due to increased investment in R&D[10] - Research and development expenses rose to CNY 7,696,788.65 in Q1 2025, up from CNY 4,618,555.66 in Q1 2024, reflecting an increase of approximately 66.8%[34] Financial Commitments and Guarantees - The company provided a guarantee for a bank credit limit of RMB 27,877,500 for its subsidiary, Hubei Kelin Bolun New Materials Co., Ltd.[21] - The company has pledged 65% of its equity in Ningxia Meibang Huanyu Chemical Co., Ltd. as collateral for a loan of RMB 100 million[21] - The company has a total of RMB 180,596,193.23 in assets under restriction, accounting for 18.40% of total assets[25] - The company has a frozen bank account with a total of RMB 32,000,000, which represents 3.26% of total assets[25] - The company has provided a guarantee for a credit limit of RMB 65 million for its subsidiary, with a guarantee amount of RMB 27,877,500[22] - The company has no significant risks or impacts from the pledged assets on its operations[24] Other Financial Metrics - Total operating costs increased to CNY 116,649,899.41 in Q1 2025 from CNY 112,933,484.89 in Q1 2024, marking an increase of about 3.0%[34] - The company reported a significant increase in financial expenses, with interest expenses rising to CNY 501,687.79 in Q1 2025 from CNY 647,062.37 in Q1 2024[34] - The company experienced a credit impairment loss of CNY -624,416.20 in Q1 2025, compared to CNY -1,128,501.04 in Q1 2024, indicating an improvement[35] - Other comprehensive income after tax for Q1 2025 was CNY -4,676.97, contrasting with CNY 738.03 in Q1 2024, showing a negative shift[35]

二、会议召开情况 2024 年度，公司董事会审计委员会共召开五次会议，具体情况如下： | 会议时间 | | 会议名称 | 具体事项 | 意见类型 | | --- | --- | --- | --- | --- | | 2024 | 年 3 | 第四届董事会审 计委员会第一次 | 《关于聘任公司财务负责人的议 | 同意 | | 月 | 27 日 | | 案》 | | | | | 会议 | | | | | | 第四届董事会审 计委员会第二次 | 《关于 2023 年审计报告的议案》 | 同意 | | | | | 《关于 2023 年年度报告及摘要的 | | | 2024 | 年 4 | | 议案》《关于董事会审计委员会对 | | | 月 | 22 日 | | 会计师事务所履行监督职责情况报 | | | | | 会议 | | | | | | | 告的议案》《关于董事会审计委员 | | | | | | 会 2023 年度履职情况报告的议案》 | | | | | | 《关于内部控制自我评价报告的议 | | | --- | --- | --- | --- | --- | | | | | 案》《关于控股股东及其他关联方 | ...